{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.3986","value":"8.953"},{"groupId":"OG001","lowerLimit":"-0.331","spread":"9.6246","upperLimit":"3.504","value":"11.022"},{"groupId":"OG002","lowerLimit":"1.214","spread":"9.4986","upperLimit":"5.026","value":"12.205"}]}],"title":"Week 52 (n=239,236,241)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.8500","value":"8.617"},{"groupId":"OG001","lowerLimit":"1.590","spread":"9.9631","upperLimit":"4.787","value":"11.032"},{"groupId":"OG002","lowerLimit":"2.749","spread":"10.4331","upperLimit":"5.920","value":"12.649"}]}],"title":"Week 104 (n=240,236,242)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"249"},{"groupId":"OG002","value":"250"}],"units":"Participants"}],"description":"The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.\n\nMeans are adjusted for baseline value, Rheumatoid Factor status and region.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nFrom Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks.","id":"OG000","title":"Placebo + Methotrexate"},{"description":"Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nSubsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6","id":"OG001","title":"Rituximab (0.5 g x 2) + Methotrexate"},{"description":"Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nSubsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6","id":"OG002","title":"Rituximab (1.0 g x 2) + Methotrexate"}],"paramType":"MEAN","populationDescription":"Intent to treat (ITT) population includes all participants who received at least one infusion. Last observation carried forward. \"n\" in each of the categories is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 52, Week 104","title":"Change From Baseline in the SF-36 Physical Health Component Summary Score at Week 52 and Week 104","type":"SECONDARY","unitOfMeasure":"Score on a scale"}